Investing.com - Panbela Therapeutics reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Panbela Therapeutics announced earnings per share of $-0.210 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.230 on revenue of $0.
Panbela Therapeutics 's are down 93% and is trading at $0.120 , still down 95.21% from its 52 week high of $2.40 set on Thursday, February 10, 2022.
Panbela Therapeutics follows other major Healthcare sector earnings this month
Panbela Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar